CXCL8 and familial pancreatic carcinoma: HuMax-IL8 was developed for the treatment of patients with advanced solid tumors in combination with nivolumab, an anti-PD-1 monoclonal antibody immune check point inhibitor (NCT02536469), and it is currently under clinical evaluation for the treatment in several other tumors, including advanced solid tumors (NCT03400332), non-small cell lung cancer (NSCLC) (NCT04123379), advanced melanoma and metastatic renal cell carcinoma (NCT04050462), pancreatic cancer (NCT02451982), and head and neck squamous cell carcinoma (NCT04848116).